STOCK TITAN

CapsoVision furnishes Q3 FY results press release via 8-K, Exhibit 99.1

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

CapsoVision, Inc. furnished a current report announcing it issued a press release with financial results for the fiscal quarter ended September 30, 2025. The press release is attached as Exhibit 99.1.

The information under Item 2.02 is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act. CapsoVision’s common stock trades on Nasdaq under the symbol CV.

Positive

  • None.

Negative

  • None.
FALSE000137832500013783252025-11-132025-11-13

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________
FORM 8-K
_________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 13, 2025
_________________________
CapsoVision, Inc.
(Exact name of registrant as specified in its charter)
_________________________
Delaware001-4270520-3369494
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification Number)
18805 Cox Avenue, Suite 250
Saratoga, California
95070
(Address of Principal Executive Offices)(Zip Code)
Registrant’s telephone number, including area code: (408)-624-1488
n/a
(Former Name or Former Address, if Changed Since Last Report)
_________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol
Name of each exchange
on which registered
common stock, $0.001 par value per shareCVThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 



Item 2.02.           Results of Operations and Financial Condition.
On November 13, 2025, the Company issued a press release announcing its financial results for the fiscal quarter ended September 30, 2025. A copy of the press release, dated November 13, 2025, is furnished hereto as Exhibit 99.1 and is incorporated herein by reference.
The foregoing information in this Item 2.02 (including the exhibit hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Item 9.01           Financial Statements and Exhibits.
The following exhibits are being filed herewith:
Exhibit
No.
Description
99.1
Press Release of CapsoVision, Inc, dated November 13, 2025.
104Cover Page Interactive Data File (embedded within the Inline XBRL document)



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CAPSOVISION, INC.
Date: November 13, 2025By:/s/ Kang-Huai (Johnny) Wang
Name:Kang-Huai (Johnny) Wang
TitleDirector, President and Chief Executive Officer

FAQ

What did CapsoVision (CV) file?

An 8-K reporting that it issued a press release with financial results for the fiscal quarter ended September 30, 2025.

Which exhibit contains the results?

The press release is attached as Exhibit 99.1.

Is the Item 2.02 information considered filed?

No. It is furnished and not deemed filed under Section 18 of the Exchange Act.

What exchange lists CapsoVision and under what ticker?

CapsoVision’s common stock trades on The Nasdaq Stock Market LLC under the ticker CV.

What period do the announced results cover?

The fiscal quarter ended September 30, 2025.

Who signed the report for CapsoVision?

It was signed by Kang-Huai (Johnny) Wang, Director, President and Chief Executive Officer.
CapsoVision, Inc.

NASDAQ:CV

CV Rankings

CV Latest News

CV Latest SEC Filings

CV Stock Data

276.38M
27.71M
40.69%
0.05%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
SARATOGA